Skip to main content

Table 6 Mean (SD) maximum percentage change in FEV1 after exercise in study 2.

From: Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

 

Baseline

PValue

Day 28

PValue

Day 56

PValue

Day 150

PValue

MEDI-528 (n = 7)*

-22.20 (4.38)

0.62

-6.49 (11.73)

0.22

-1.40 (2.27)

0.17

-5.04 (3.91)

0.52

Placebo (n = 2)

-20.20 (4.16)

 

-12.60 (1.53)

 

-20.10 (7.41)

 

-15.20 (15.48)

 
  1. *For day 150, n = 6. P values are based on two-sample t test between placebo and MEDI-528 groups.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us